Zhejiang Jiuzhou Pharm Co Ltd (603456) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zhejiang Jiuzhou Pharm Co Ltd (603456) has a cash flow conversion efficiency ratio of 0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥496.86 Million ≈ $72.71 Million USD) by net assets (CN¥8.82 Billion ≈ $1.29 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 603456 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Zhejiang Jiuzhou Pharm Co Ltd - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Zhejiang Jiuzhou Pharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zhejiang Jiuzhou Pharm Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhejiang Jiuzhou Pharm Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ivanhoe Electric Inc.
NYSE MKT:IE
|
-0.094x |
|
Beijer Alma AB (publ)
ST:BEIA-B
|
0.066x |
|
Agios Pharm
NASDAQ:AGIO
|
-0.107x |
|
Kfin Technologies Limited
NSE:KFINTECH
|
0.108x |
|
Tien Phong Commercial Joint Stock Bank
VN:TPB
|
0.690x |
|
Greif Bros Corporation
NYSE:GEF
|
0.038x |
|
Wuxi Shangji Automation Co Ltd
SHG:603185
|
0.051x |
|
Bukit Asam Tbk PT
JK:PTBA
|
0.087x |
Annual Cash Flow Conversion Efficiency for Zhejiang Jiuzhou Pharm Co Ltd (2008–2025)
The table below shows the annual cash flow conversion efficiency of Zhejiang Jiuzhou Pharm Co Ltd from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see Zhejiang Jiuzhou Pharm Co Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥8.79 Billion ≈ $1.29 Billion |
CN¥1.82 Billion ≈ $266.94 Million |
0.208x | +80.17% |
| 2024-12-31 | CN¥8.61 Billion ≈ $1.26 Billion |
CN¥991.66 Million ≈ $145.11 Million |
0.115x | -27.75% |
| 2023-12-31 | CN¥8.53 Billion ≈ $1.25 Billion |
CN¥1.36 Billion ≈ $199.06 Million |
0.159x | -30.14% |
| 2022-12-31 | CN¥5.37 Billion ≈ $786.02 Million |
CN¥1.23 Billion ≈ $179.37 Million |
0.228x | +54.17% |
| 2021-12-31 | CN¥4.58 Billion ≈ $669.78 Million |
CN¥677.52 Million ≈ $99.14 Million |
0.148x | +14.09% |
| 2020-12-31 | CN¥3.09 Billion ≈ $451.60 Million |
CN¥400.39 Million ≈ $58.59 Million |
0.130x | -33.08% |
| 2019-12-31 | CN¥2.86 Billion ≈ $418.27 Million |
CN¥554.16 Million ≈ $81.09 Million |
0.194x | +103.41% |
| 2018-12-31 | CN¥2.78 Billion ≈ $406.52 Million |
CN¥264.78 Million ≈ $38.75 Million |
0.095x | +4.63% |
| 2017-12-31 | CN¥2.68 Billion ≈ $392.28 Million |
CN¥244.20 Million ≈ $35.73 Million |
0.091x | +71.11% |
| 2016-12-31 | CN¥2.57 Billion ≈ $375.60 Million |
CN¥136.65 Million ≈ $20.00 Million |
0.053x | -4.69% |
| 2015-12-31 | CN¥2.52 Billion ≈ $368.13 Million |
CN¥140.53 Million ≈ $20.56 Million |
0.056x | +769.79% |
| 2014-12-31 | CN¥1.58 Billion ≈ $231.68 Million |
CN¥10.17 Million ≈ $1.49 Million |
0.006x | -97.68% |
| 2013-12-31 | CN¥736.75 Million ≈ $107.81 Million |
CN¥203.86 Million ≈ $29.83 Million |
0.277x | +7.08% |
| 2012-12-31 | CN¥597.08 Million ≈ $87.37 Million |
CN¥154.28 Million ≈ $22.58 Million |
0.258x | +7.20% |
| 2011-12-31 | CN¥460.54 Million ≈ $67.39 Million |
CN¥111.01 Million ≈ $16.24 Million |
0.241x | -21.27% |
| 2010-12-31 | CN¥343.94 Million ≈ $50.33 Million |
CN¥105.30 Million ≈ $15.41 Million |
0.306x | -38.31% |
| 2009-12-31 | CN¥245.87 Million ≈ $35.98 Million |
CN¥122.03 Million ≈ $17.86 Million |
0.496x | +5.09% |
| 2008-12-31 | CN¥175.41 Million ≈ $25.67 Million |
CN¥82.84 Million ≈ $12.12 Million |
0.472x | -- |
About Zhejiang Jiuzhou Pharm Co Ltd
Zhejiang Jiuzhou Pharmaceutical Co., Ltd operates as contract development and manufacturing organization (CDMO) company in China and internationally. The company offers small molecule, drug product, and peptide CDMO services. It also involved in business related to supporting the development of new drugs and pharmaceuticals. It serves global pharmaceutical companies, biotechnology companies, and … Read more